Trial reportChinese journal of integrative medicine2026
Efficacy and Safety of Tonifying Kidney-Yang Decoction for Vascular Cognitive Impairment: A Multicenter Double-Blind Randomized Controlled Trial.
Trial report in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of Tonifying Kidney-Yang Decoction (TKYD) in treating patients with vascular cognitive impairment (VCI) characterized by Shen (Kidney)-yang deficiency (SYD) syndrome.
methodsThis multicenter, double-blind, randomized, and placebo-controlled clinical trial was conducted in 4 hospitals of China from September 2020 to December 2021. Eligible patients were enrolled and randomly assigned in a 1:1 ratio to receive either TKYD granules or placebo twice daily for 12 weeks. The primary outcomes were changes in scores of the Beijing Version of the Montreal Cognitive Assessment (MoCA-BJ) and Shen-Yang Deficiency Syndrome Scale (SYDSS) from baseline to week 12. The secondary outcomes included scores of the Mini-Mental State Examination (MMSE), Color Trails Test interference index, Stroop Color and Word Test-Stroop interference effect, Neuropsychiatric Inventory (NPI), Apathy Evaluation Scale-Clinician Version, and Activities of Daily Living scales. Safety was monitored throughout the trial.
resultsA total of 120 patients completed the trial, including 63 and 57 in the TKYD and placebo groups, respectively. After 12 weeks of treatment, the TKYD group exhibited a significantly greater increase in MoCA-BJ (change: 1.40 vs. 0.11) and reduction in SYDSS scores (change: -12.17 vs. -7.46) than the placebo group (P<0.05 or P<0.01). Regarding specific domains of MoCA-BJ, TKYD exhibited significantly greater improvements in visuospatial/executive function, orientation and delayed recall (P<0.05 or P<0.01). In terms of change scores in SYDSS, TKYD also showed greater reductions in diarrhea before dawn, lumbago, and weakness of knees (P<0.05 or P<0.01). For the secondary outcomes, the TKYD group exhibited significantly higher MMSE scores and lower NPI scores compared with the placebo group (P<0.05 or P<0.01). No treatment-related adverse events were reported.
conclusionTKYD is effective and safe for improving cognitive function and alleviating SYD symptoms in VCI patients with SYD syndrome. (Registration No. ChiCTR1900025713).
Indexed as
Identifiers
41760868What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.